Asarina Pharma AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASAP.ST research report →
Companywww.asarinapharma.com
Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its flagship product is Sepranolone, which is used for the treatment of menstrual migraine and Tourette syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016.
- CEO
- Peter Nordkild
- IPO
- 2018
- Employees
- 5
- HQ
- Solna, SE
Price Chart
Valuation
- Market Cap
- $633.96K
- P/E
- -0.05
- P/S
- 0.00
- P/B
- 0.38
- EV/EBITDA
- 0.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -157.86%
- ROIC
- -485.95%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-12,828,000 · 3.43%
- EPS
- $-0.57 · 19.72%
- Op Income
- $-14,640,000
- FCF YoY
- -20.96%
Performance & Tape
- 52W High
- $1.31
- 52W Low
- $0.03
- 50D MA
- $0.10
- 200D MA
- $0.69
- Beta
- 0.17
- Avg Volume
- 347.45K
Get TickerSpark's AI analysis on ASAP.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ASAP.ST Coverage
We haven't published any research on ASAP.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ASAP.ST Report →